Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Davina Moussa"'
Autor:
Thomas M. Habermann, Chih Jian Lih, Ranjana H. Advani, Davina Moussa, Andre Goy, Paul M. Barr, Rebecca Elstrom, Nathan Fowler, Fong Clow, Betty Y. Chang, Maria Fardis, Darrin M. Beaupre, Brian Munneke, John F. Gerecitano, Ryan M. Young, Wyndham H. Wilson, Louis M. Staudt, Roland Schmitz, Stefania Pittaluga, Vaishalee P. Kenkre, Yandan Yang, P. Mickey Williams, George E. Wright, Andrei R. Shustov, Julie M. Vose, Jacqueline C. Barrientos, Jesse McGreivy, Sven de Vos, Arthur L. Shaffer, Kristie A. Blum
Publikováno v:
Nat Med
The two major subtypes of diffuse large B cell lymphoma (DLBCL)—activated B cell–like (ABC) and germinal center B cell–like (GCB)—arise by distinct mechanisms, with ABC selectively acquiring mutations that target the B cell receptor (BCR), fo
Autor:
Juthamas Sukbuntherng, Purvi Jejurkar, Anh L. Tran, Stephen L. Chan, Danelle F. James, Davina Moussa, David Loury
Publikováno v:
Journal of Clinical Oncology. 31:7056-7056
7056 Background: Ibrutinib is a first-in-class selective small molecular inhibitor of Bruton’s tyrosine kinase (BTK) under development for the treatment of B-cell malignancies. Because of covalent binding to cys-481 of BTK, ibrutinib has a sustaine
Autor:
Davina Moussa, Nikoletta Lendvai, Laurence Elias, Stella Chang, Yu-Tzu Tai, Paul G. Richardson, Ravi Vij, Jesus G. Berdeja, Carol Ann Huff, Joseph J. Buggy, Betty Chang
Publikováno v:
Blood. 120:4039-4039
Abstract 4039 Introduction: Bruton tyrosine kinase (Btk) is essential in the development and function of B cells through normal B cell receptor signaling, and it is down-regulated in non-malignant plasma cells. This is not the case in malignant plasm
Autor:
Sven de Vos, Mickey Williams, John F. Gerecitano, George E. Wright, Paul M. Barr, Davina Moussa, Joseph J. Buggy, Jason Lih, Ranjana H. Advani, Lori Kunkel, Andrei R. Shustov, Sriram Balasubramanian, Wyndham H. Wilson, Jesse McGreivy, Mei Cheng, Andre Goy, Louis M. Staudt, Roland Schmitz, Stefania Pittaluga, Vaishalee P. Kenkre, Yandan Yang, Kristie A. Blum
Publikováno v:
Blood. 120:686-686
686 Background DLBCL has two molecular subtypes, termed activated B cell-like (ABC) and germinal center B cell-like (GCB), with ABC DLBCL being less curable with current therapy. The survival of ABC but not GCB DLBCL cell lines is sustained by “chr